Dr. Jameel Muzaffar, MD

Dr. Muzaffar practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Muzaffar's NPI, 1497954564, was assigned on July 17, 2007. Dr. Muzaffar holds North Carolina license 2023-00157.

Dr. Muzaffar's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Muzaffar's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Muzaffar is also affiliated with Duke University Hospital. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Muzaffar to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Muzaffar practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Muzaffar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Muzaffar's licenses on file in 3 states: North Carolina, Florida and Missouri.

CMS data shows 354 Medicare services from Dr. Muzaffar across 5 procedure codes in 2024, for 144 Medicare patients. Medicare paid $31,773 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 144 Medicare patients who saw Dr. Muzaffar in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 69% have high cholesterol. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Muzaffar's median patient age at 71, with 30% women.

In 2024, Dr. Muzaffar wrote 252 Medicare Part D claims for 57 patients. 78% of them were for generic drugs. CMS names the drug for 181 of them, across 8 drugs with 11 or more claims each, at $355,860 in total drug cost. In 2023, CMS named 36 claims across 2 drugs.

Dr. Muzaffar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Muzaffar as offering telehealth.

Dmand AI links 109 papers to Dr. Muzaffar, published from 2006 to 2025. 2024 was the busiest year, with 15. The most frequent topics are Cochlear Implantation, Cochlear Implants and Head and Neck Neoplasms. Dr. Muzaffar has published most often in J Int Adv Otol. Dr. Muzaffar's most frequent co-authors are Christine H. Chung, MD, Kedar Shirish Kirtane, MD and Matthew Edward Smith, MD.

Dmand AI links Dr. Muzaffar to 10 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Neoplasms, Squamous Cell, Carcinoma, Adenoid Cystic and Squamous Cell Carcinoma of Head and Neck. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.

CMS Open Payments shows 34 general payments to Dr. Muzaffar from 7 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 66% of the total. Merck Sharp & Dohme Corporation paid the most, $19,930.